C.F.R. » Title 45 » SUBCHAPTER E—PRICE TRANSPARENCY › PART 182—PRICE TRANSPARENCY FOR COVID-19 DIAGNOSTIC TESTS › Subpart A—General Provisions

45 C.F.R. § 182.20

Definitions

Read at: eCFRecfr.gov CornellLII GovInfogovinfo.gov CasesGoogle Scholar

The following definitions and abbreviated terms apply to this part:

Cash price means the charge that applies to an individual who pays cash (or cash equivalent) for a COVID-19 diagnostic test.

COVID-19 for purposes of this part is the abbreviated term for the virus called SARS-CoV-2 and the disease it causes, called coronavirus disease 2019.

Diagnostic test for COVID-19 (“COVID-19 diagnostic test”) means a COVID-19 in vitro diagnostic test described in section 6001 of the Families First Coronavirus Response Act (Pub. L. 116-127, March 18, 2020), as amended by section 3201 of the CARES Act (Pub. L. 116-136, March 27, 2020).

Provider of a diagnostic test for COVID-19 (“provider”) means any facility that performs one or more COVID-19 diagnostic tests.

Notes of Decisions
Cited in 1 case (1 in the last 5 years), 2024–2024 · leading case: Murphy Med. Assocs., LLC v. EmblemHealth, Inc. (D. Conn. 2024).
Sort: Relevance Newest Treatment
Murphy Med. Assocs., LLC v. EmblemHealth, Inc. (D. Conn. 2024). “” 45 C.F.R. § 182.20 . Regulatory agencies described their expectation that “the ‘cash price’ established by the provider will be generally similar to, or lower than, rates negotiated with in-network plans and insurers.”
Annotations are extracted automatically from the opinions in the Syfert caselaw corpus and ranked by authority, recency, and treatment. Dots show Syfertize treatment of the citing case itself.